Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR

BACKGROUND: Non-small cell lung cancer (NSCLC) expressed high levels of epidermal growth factor receptor (EGFR). Gefitinib (Iressa) has demonstrated clinical efficacy in NSCLC patients harboring EGFR mutations or refractory to chemotherapy. However, most of NSCLC patients are with wild type EGFR, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Shu-Yan, Ding, Hui-Rong, Zhao, Wei, Teng, Fei, Li, Ping-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040364/
https://www.ncbi.nlm.nih.gov/pubmed/24884778
http://dx.doi.org/10.1186/1472-6882-14-165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040364/
https://www.ncbi.nlm.nih.gov/pubmed/24884778
http://dx.doi.org/10.1186/1472-6882-14-165

Ejemplares similares